Tuesday, November 1, 2016

miRagen Therapeutics Raises $40M, Goes Public In Reverse Merger

Boulder-based biopharmaceuticals developer Miragen Therapeutics has raised $40M, and has hit the public markets, in a reverse merger with California-based Signal Genetics. According to miRagen, it is acquiring approximately 96 percent of Signal's outstanding common stock, and has also raised $40M in financing from an investment syndicate that includes Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Miragen says that, if the transaction is consummated, Signal's name will be changed to Miragen Therapeutics, Inc., and that it will change its symbol Signal Genetics' current SGNL, to MGEN, trading on the NASDAQ Capital Market.